Implantica releases 2021 annual report
Medical technology firm Implantica has published its annual report for the 2021 financial year. The document is now available via the company’s investor relations website.
Implantica AG has released its annual report for the 2021 fiscal year, detailing the company's operational and financial status. The Sweden-listed firm focuses on developing medical implants designed for chronic conditions.
CEO Peter Forsell stated that during 2021, the company focused on executing its market strategy for the RefluxStop device and advancing its pipeline of e-health implant solutions. RefluxStop, which is CE-marked for the treatment of acid reflux, is currently available in several European markets, including the United Kingdom, Germany, and Switzerland.
Implantica’s business model centers on two primary technology platforms: an e-health system for remote monitoring and a wireless energy platform for powering implants. The company’s shares trade on the Nasdaq First North Premier Growth Market.
The annual report provides a full overview of the company’s activities and strategic direction for the coming periods.